Chronic Pain — 13 September 2013

By Pat Anson, Editor

It was one year ago that Millennium Laboratories introduced a new genetic test that one doctor hailed as the “Holy Grail” of patient drug therapy: a test that could tell physicians why some patients react poorly or differently to pain medication.

Some even predicted it would revolutionize the field of pain management.

Flash forward a year to PAINWeek in Las Vegas, the same health care conference where Millennium announced the launch of its pharmacogenetic (PGT) test in 2012.

At a breakfast symposium attended by hundreds of pain management practitioners, a Millennium representative asked for a show of hands. How many had used the PGT test in the past year?

Only a handful of hands went up.

The revolution is off to a slow start.

“We know that managing pain patients is a trial and error approach many times,” says Jennifer Strickland, PharrmD, Millennium’s vice president of clinical strategy.

“I think that as the literature evolves and as we learn more about this area, it will become more standard of care.”

Read more at National Pain Report.


About Author

Pat Anson, Editor

Pat is Editor in Chief of American News Report. He is a veteran journalist and a former correspondent and producer for HealthWeek (PBS), Nightly Business Report (PBS) and other nationally syndicated shows. Pat has won numerous journalism awards, including a Golden Mike award for investigative reporting.

(0) Readers Comments

Comments are closed.